Terminated NCT00857818
This study was terminated in Canada. It focuses on schizophrenia.
Multiple locations, including Calgary Why is this study shown? This study includes Schizophrenia among several conditions.
Bipolarity, Schizophrenia Drug i A study involving a medication or substance. From 18 Years to 65 Years
Countries Canada
Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition Bipolarity, Schizophrenia Recruitment unclear EUCTR 2017-000497-11
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.
In Austria Why is this study shown? This study includes Schizophrenia among several conditions.
Bipolarity, Schizophrenia Drug
Countries Austria, Germany, Italy, ...
Sponsor Alkermes Inc
Condition Bipolarity, Schizophrenia Completed NCT03379597
This study is completed in China. It is testing dietary Fiber and Probiotics Treatment for schizophrenia.
In Changsha Why is this study shown? This study includes Schizophrenia among several conditions.
Bipolarity, Schizophrenia Drug From 18 Years to 65 Years
Countries China
Sponsor Central South University
Condition Bipolarity, Schizophrenia Completed NCT07549581
This study is completed in the United States. It is testing SEP-380135 for depression.
In Los Alamitos Why is this study shown? This study includes Schizophrenia among several conditions.
Depression, Schizophrenia, ... Drug From 18 Years to 55 Years
Countries United States
Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition Depression, Schizophrenia, ... Completed NCT03818256
This study is completed in the United States. It is testing safety, Efficacy, and Pharmacokinetics of Miricorilant for schizophrenia.
Multiple locations, including Bentonville Why is this study shown? This study includes Schizophrenia among several conditions.
Bipolarity, Schizophrenia Drug From 18 Years to 65 Years
Countries United States
Sponsor Corcept Therapeutics
Condition Bipolarity, Schizophrenia Completed NCT01206517
This study is completed. It is testing sublingual Asenapine for schizophrenia.
Location not clearly listed Why is this study shown? This study includes Schizophrenia among several conditions.
Bipolarity, Schizophrenia Drug From 10 Years to 17 Years
Countries
Sponsor Organon and Co
Condition Bipolarity, Schizophrenia Completed NCT04030143
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Little Rock Why is this study shown? This study includes Schizophrenia among several conditions.
Bipolarity, Schizophrenia Drug From 18 Years to 64 Years
Countries United States
Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition Bipolarity, Schizophrenia Completed NCT03854409
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Little Rock Why is this study shown? This study includes Schizophrenia among several conditions.
Bipolarity, Schizophrenia Drug From 18 Years to 64 Years
Countries United States
Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition Bipolarity, Schizophrenia Completed NCT03386851
This summary needs review. Please check the official study record and contact the research team for details.
In Gwangju Why is this study shown? This study includes Schizophrenia among several conditions.
Bipolarity, Schizophrenia Observational i A study where researchers collect information without assigning a treatment. Over 19 Years
Countries South Korea
Sponsor Korea Otsuka Pharmaceutical Co., Ltd.
Condition Bipolarity, Schizophrenia Withdrawn NCT01981811
This study was withdrawn in the United States. It is testing Medical Information Device #1 for schizophrenia.
Multiple locations, including Cerritos Why is this study shown? This study includes Schizophrenia among several conditions.
Bipolarity, Schizophrenia Drug From 18 Years to 65 Years
Countries United States
Sponsor Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition Bipolarity, Schizophrenia Completed NCT01629355
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Balsfjord Why is this study shown? This study includes Schizophrenia among several conditions.
Bipolarity, Schizophrenia Observational From 18 Years to 70 Years
Countries Norway
Sponsor University Hospital of North Norway
Condition Bipolarity, Schizophrenia Completed NCT00666432
This summary needs review. Please check the official study record and contact the research team for details.
Multiple locations, including Hartford Why is this study shown? This study includes Schizophrenia among several conditions.
Bipolarity, Schizophrenia Observational Over 15 Years
Countries United States
Sponsor University of Maryland, Baltimore
Condition Bipolarity, Schizophrenia